Beryl Drugs Ltd vs Laurus Labs Limited

A side-by-side comparison of Beryl Drugs Ltd (BERYLDRUGSLTD) and Laurus Labs Limited (LAURUSLABS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Laurus Labs Limited leads BERYLDRUGSLTD vs LAURUSLABS on 11 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth02
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

19.60
P/E ratio
125.08
1.24
P/B ratio
19.74
0.00%
Dividend yield
0.10%
₹1.14
EPS
₹16.47

Profitability

LAURUSLABS takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

4.33%
Return on equity
16.77%
10.15%
Return on capital
17.58%
5.86%
EBITDA margin
26.09%
2.74%
Net margin
13.07%

Growth

LAURUSLABS takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-11.16%
Revenue CAGR (3Y)
4.09%
-14.58%
Profit CAGR (3Y)
3.91%

Size & financial health

LAURUSLABS takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹11 Cr
Market cap
₹1.11L Cr
₹21 Cr
Revenue
₹6,813 Cr
₹1 Cr
Net profit
₹890 Cr
0.25
Debt / equity
0.45
Beryl Drugs Ltd
  • + ["Company has reduced debt.", "Debtor days have improved from 79.1 to 39.5 days.", "Company's working capital requirements have reduced from 55.1 days to 39.3 days"]
  • − ["Though the company is reporting repeated profits, it is not paying out dividend", "The company has delivered a poor sales growth of 6.60% over past five years.", "Promoter holding is low: 27.8%", "Company has a low return on equity of 6.42% over last 3 years."]
Laurus Labs Limited
  • + []
  • − ["Stock is trading at 20.99 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
Beryl Drugs Ltd full analysis Laurus Labs Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.